Danish pharmaceutical company Novo Nordisk A/S (CPH:NOVO-B) (NYSE:NVO) announced on Friday that the US Food and Drug Administration (FDA) has accepted its New Drug Application (NDA) submission for an investigational once-daily, 25 mg oral formulation of Wegovy (semaglutide) for chronic weight management in adults living with obesity or overweight with one or more comorbid conditions and to reduce the risk of major adverse cardiovascular events (MACE) in adults with overweight or obesity and established cardiovascular disease.

If approved, Wegovy will become the first oral formulation of a GLP-1 indicated for chronic weight management.

The application is based on results from OASIS 4, a 64-week phase 3 randomised, controlled trial evaluating the efficacy and safety of once-daily oral semaglutide 25 mg versus placebo in 307 adults with obesity (BMI >/= 30 kg/m2) or overweight (BMI >/= 27 kg/m2) with one or more comorbidities.1,3 Patients with diabetes were excluded.1,3

OASIS 4 included a 12-week dose escalation period and a 7-week off-treatment follow-up period. In total, 307 participants were randomised 2:1 ratio to once-daily oral semaglutide 25 mg or placebo, as an adjunct to lifestyle intervention for 64 weeks.

The FDA action date to decide on the Wegovy oral formulation NDA will be in Q4 2025.